Every Form 4 that Xilio Therapeutics, Inc. (XLO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XLO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XLO filings page.
Xilio Therapeutics director Bello Akintunde Olatokumbo received a grant of stock options for 5,000 shares of common stock. The options carry an exercise price of 7.99 per share and expire on June 10, 2036.
The award will vest as to 100% of the underlying 5,000 shares on the earlier of June 11, 2027 or Xilio Therapeutics’ next annual meeting of stockholders following the grant date, subject to his continued service. Following this grant, he holds 5,000 stock options, reflecting a routine compensation-related equity award rather than an open-market purchase or sale.
Xilio Therapeutics director Shannon James Samuel received a grant of stock options for 5,000 shares of common stock at an exercise price of $7.99 per share. These options vest 100% on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, contingent on continued service.
Following the grant, Samuel holds 5,000 options directly.
Xilio Therapeutics director Daniel J. Curran received a grant of stock options covering 5,000 shares of common stock. The options have an exercise price of $7.99 per share and bring his total option holdings reported in this filing to 5,000 derivative shares.
The award was granted as of June 11, 2026 and will vest as to 100% of the underlying shares on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders following the grant date, provided he continues to serve the company through the vesting date. This is a compensation-related grant rather than an open-market purchase or sale.
Xilio Therapeutics director Xu Yuan received a grant of stock options as equity compensation. The award covers 5,000 options to buy common stock at an exercise price of $7.99 per share, expiring on June 10, 2036.
The options were granted on June 11, 2026 and will vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting after the grant date, as long as Xu Yuan continues to serve the company through that vesting date. After this grant, the filing shows Xu Yuan holding 5,000 derivative securities (stock options).
Xilio Therapeutics director Robert W. Ross received a stock option grant covering 5,000 shares of common stock. The option has an exercise price of $7.99 per share and expires on June 10, 2036. It will vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, assuming he remains in service. This is a compensation-related award, not an open-market share purchase or sale.
Xilio Therapeutics director Sara Bonstein received a grant of stock options covering 5,000 shares of common stock. The options have an exercise price of $7.99 per share and expire on June 10, 2036. They vest 100% on June 11, 2027 or at the next annual stockholder meeting, whichever occurs first, assuming continued service.
Xilio Therapeutics director Aoife Brennan received a new stock option grant. The award covers 5,000 shares of common stock at an exercise price of $7.99 per share, expiring on June 10, 2036. It vests 100% on June 11, 2027 or at the next annual stockholder meeting, subject to continued service.
Xilio Therapeutics director Cheryl R. Blanchard received a grant of stock options covering 10,000 shares of common stock. These options have an exercise price of $8.40 per share and expire on April 14, 2036.
The award was granted on April 15, 2026 and will vest in three equal installments on April 15, 2027, April 15, 2028 and April 15, 2029, as long as she continues to serve the company through each vesting date. Following this grant, she holds 10,000 options directly.
Xilio Therapeutics, Inc. director Shannon James Samuel completed an open-market purchase of common stock. On March 26, 2026, Samuel bought 5,000 shares at a weighted average price of $8.79 per share, increasing direct holdings to 10,000 shares. The reported ownership reflects a 1-for-14 reverse stock split effective March 13, 2026.
GILEAD SCIENCES, INC. reported open-market purchase transactions in a Form 4 filing for XLO. The filing lists transactions totaling 3,739,000 shares at a weighted average price of $0.53 per share. Following the reported transactions, holdings were 40,384,266 shares.
Xilio Therapeutics, Inc. reported a Form 4 for its SVP, Finance and Accounting, reflecting new stock option grants and an option repricing tied to the company’s 2025 Stock Incentive Plan. Following stockholder approval of the 2025 plan on November 21, 2025, the executive received a stock option for 131,700 shares of common stock at an exercise price of $0.841 per share, vesting in 36 equal monthly installments beginning December 21, 2025.
The filing also shows a one-time option repricing effective November 21, 2025, reducing the exercise price of several existing options to $1.00 per share, while keeping their original vesting and expiration terms, except that exercises prior to November 21, 2026 must use the original exercise price. These options include grants originally priced at $3.17, $2.785 and $1.08 with expirations in 2033 and 2034.
Xilio Therapeutics (XLO) reported insider equity activity for its Chief Financial Officer on a Form 4. The Board approved a new 2025 Stock Incentive Plan on October 8, 2025, and stockholders approved the plan on November 21, 2025.
Under this plan, the CFO received stock options to purchase 925,000 shares of common stock at an exercise price of $0.841 per share, expiring on October 7, 2035. These options vest in 36 equal monthly installments over three years beginning on December 21, 2025, contingent on continued service.
The filing also details a one-time option repricing effective November 21, 2025, that reduced the exercise price of several existing stock option grants to $1.50 per share, while keeping their original vesting and expiration terms. If any repriced option is exercised before November 21, 2026, the original, higher exercise price must be paid.
Xilio Therapeutics (XLO) reported an equity compensation update for its chief medical officer. Under the new 2025 Stock Incentive Plan, approved by stockholders on November 21, 2025, the officer received a stock option for 625,000 shares at an exercise price of $0.841 per share. These options vest in 36 equal monthly installments starting December 21, 2025, so the grant is earned gradually over three years.
The filing also records a one-time option repricing effective November 21, 2025. Several existing stock options with higher exercise prices, including grants for 44,210 and 106,000 shares, were modified so that the exercise price is reduced to $1.50 per share. If any repriced option is exercised before November 21, 2026, the original, higher exercise price still applies, while all other vesting and expiration terms remain unchanged.
Xilio Therapeutics (XLO) reported equity compensation changes for its President and CEO, who is also a director, in a Form 4. The filing shows a new stock option grant covering 2,075,000 shares of common stock at an exercise price of $0.841 per share under the 2025 Stock Incentive Plan, which was approved by stockholders on November 21, 2025. These options vest in 36 equal monthly installments over three years beginning on December 21, 2025, contingent on continued service.
The filing also details a one-time option repricing effective November 21, 2025, reducing the exercise price of several existing stock options to $1.50 per share. If any repriced option is exercised before November 21, 2026, the original higher exercise price must be paid, and all other vesting and expiration terms for those options remain unchanged.